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Highly purified human polymorphonuclear leucocyte collagenase cleaved human e-l-proteinase inhibitor (~I-PI) at the carboxyl site of Phe asz (PT). 
The inhibitor was thereby rapidly inactivated and generated a primary degradation product as shown by reverse-phase HPLC and N-terminal se- 
quencing. Prolonged incubation of the modified inhibitor with polymorphonuclear leucocyte collagenase l d to the generation of a secondary degra- 
dation product with additional cleavage at the carboxyl site of Pro 3s7 (Pz). 
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I. INTRODUCTION 2. MATERIALS AND METHODS 
Polymorphonuclear (PMN) leucocytes have diverse 
roles which include the phagocytosis of bacterial 
microorganisms, the regulation of immune and inflam- 
matory processes and extracellular matrix degradation. 
Furthermore, PMN leucocytes are believed to play an 
important role in the development of pulmonary em- 
physema, which is due to uncontrolled proteolysis of 
lung tissue in the absence of sufficient quantities of 
Cel-proteinase inhibitor (Crl-PI). Individuals with genetic 
Crl-PI deficiency are predisposed to emphysema [1]. 
The normal function of crt-PI therefore seems to be the 
inhibition of PMN leucocyte lastase [2], which nor- 
mally protects the elastic lung fibers against proteolytic 
degradation. 
It is important to note that, although a genetic defect 
in cet-PI production may result in the development of 
emphysema, this disease occurs frequently in in- 
dividuals with apparently normal inhibitor levels. For 
this reason the investigation of oxidative [3,4] or pro- 
teolytic [5-13] inactivation of oq-PI by bacterial or 
human proteinases becomes an important feature in the 
regulation of elastic fiber turnover of the lung. 
The discovery that a metalloproteinase secreted from 
PMN leucocytes inactivates crt-PI [12,13] led to a new 
understanding of the pathogenesis of pulmonary em- 
physema. We now conclude that the proteolytic inac- 
tivation of oq-PI is due to PMN leucocyte collagenase. 
oq-PI was a generous gift from Behringwerke, Marburg, FRG. 
2.1. Purification of PAIN leucocyte collagenase, activation and 
enzyme assay 
Leucocytes were isolated from buffy coat according to the method 
described in [14]. PMN leucocyte collagenase was purified to 
homogeneity as recently published [15]. Proenzyme activation was 
achieved by incubation with 1 mM HgC12 for 2 h at 37°C. The activi- 
ty of collagenase was determined by the degradation of the synthetic 
octapeptide (dinitrophenyl-Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg- 
OH) as described in [16]. Alternatively, the degradation of soluble 
type I collagen at 25°C was shown by SDS-PAGE. 
2.2. Proteolytic inactivation of cel-Pl 
1 mg human ce~rPI was incubated with 5/~g activated PMN 
leucocyte collagenase at 37°C for 4 and 20 h. 
2.3. Separation of ai-Pl degradation products by reverse-phase 
HPLC 
The degradation products of human oq-P1 inactivated by PMN 
leucocyte collagenase were subjected to a Bakerbond wide pore 
C4-column (4.9 x 250 mm) after 1 h or 24 h incubation time. The 
separations were performed at a constant flow rate of 1 ml /min using 
a linear gradient from 0-80% acetonitrile (Fig. 1). 
2.4. Sequence determination 
Aminoterminal sequence determinations of the individual degrada- 
tion products isolated by reverse-phase HPLC were performed on 
Immobilon-P membrane (Millipore, Bedford, USA), which was 
pretreated with 0.5 mg polybrene to ensure binding of peptides and 
applied to a microsequencer (Model 810, Knauer, Berlin, FRG). The 
Pth amino-acid separations were performed online on an Applied 
Biosystems Pth-C18-column (220 x 2.1 mm) at a flow rate of 
0.24 ml /min using the buffer system of Hunkapiller [17]. 
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2.5. SDS-PAGE 
SDS-PAGE was performed according to the method of Laemmli 
[18]. The proteins were visualized by silver staining as previously 
described by Heukeshoven and Dernick [19]. 
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Fig. 1. Reverse-phase HPLC of Cel-Pl degradation products. 4 mg 
ce~-PI was degraded by incubation with 10/zg purified PMN 
collagenase for 1 h (a) and 24 h (b) at 37°C. A, peptide A (primary 
degradation product; 1 h at 37°C); B, peptide B (secondary 
degradation product; 24 h at 37°C). 
3. RESULTS AND DISCUSSION 
The rapid proteolytic inactivation of o~-PI by highly 
purified PMN leucocyte collagenase was shown by 
SDS-PAGE (not shown), reverse-phase HPLC and N- 
terminal sequence determination. The analysis of the 
proteolytic inactivation of cel-PI by PMN leucocyte col- 
lagenase showed the generation of a primary degrada- 
tion product after 1 h at 37°C (Fig. la, peptide A). 
PMN leucocyte collagenase cleaved the Phe352-Leu 353 
peptide bond (PT -P6)  [20] of the native cet-PI. The pro- 
teolytic cleavage at the carboxyl site of Phe 35z (P7) led 
to the inactivation of the inhibitor (Fig. 2). Inactivation 
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Fig. 2. Proteolytic inactivation of oq-PI by PMN collagenase. 
Inactivation of o~-Pl by PMN collagenase after 1 h at 37°C. 
Inhibition of the inactivation of cq-Pl by PMN collagenase in the 
presence of 50 mM EDTA. The inhibition of bovine trypsin (12.5/xg) 
by Cel-PI (2 mg/ml) is shown. 
of cel-PI by PMN leucocyte collagenase was inhibited 
by EDTA and 1,10-phenanthroline. Further incubation 
at 37°C resulted in additional cleavage of the 
Pro357-Met358-(p2-P1) peptide bond (Fig. lb, peptide 
B). 
The serine proteinases, elastase, trypsin and 
chymotrypsin, which are inhibited by complex forma- 
tion with Cel-PI, cleave the inhibitor at the Met358-Ser 359 
(P1-P~) peptide bond, that corresponds to the reactive 
site of the inhibitor [21]. The X-ray crystallographic 
structure of the modified (reactive site cleaved) Cel-PI 
showed that a dramatic structural change accompanied 
the cleavage of the reactive site, since Met 358 (P0 and 
Ser 359 (P[) were located at opposite sites of the 
modified inhibitor [22]. The peptide which was 
generated upon cleavage of the reactive site remained 
bound to the inhibitor by means of non-covalent in- 
teractions. 
It was shown during the last two decades that O~l-PI 
is susceptible to proteolytic inactivation by different 
proteolytic enzymes of bacterial [5,6] and human origin 
[9,11-13] (for details: see Table I). The interesting fact 
that secreted PMN leucocyte collagenase can 
catalytically cleave and inactivate Cel-PI in the 
Table I 
Cleavage sites of the proteolytic inactivation of human Otl-Pl by different proteolytic enzymes 
Residue no. 350 360 
Ala-Met-Phe-Leu-Glu-Ala-lle-Pro-Met-Ser-Ile-Pro-Pro-Glu-Val-Lys-Phe-Asn-Lys- 
I" t T t I" 
V IV I11 II I 
Cleavage site I: Cathepsin L [9], Serratia marcescens metalloproteinase [6] 
Cleavage sitel l :  Pseudomonas aeruginosa [7], macrophage lastase [11], PMN collagenase 
(secondary product) (this paper) 
Cleavage site II1: Cathepsin L [9], Staphylococcus aureus cysteine and serine proteinase [5] 
Cleavage site IV: Staphylococcus aureus metalloproteinase [5], secreted PMN metalloproteinase 
[12,13], PMN collagenase (primary product) (this paper) 
Cleavage site V: Crotalus adamanteus proteinase II [8] 
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prote inase-sens i t ive  r g ion may cont r ibute  to a per- 
sist ing act iv i ty o f  PMN leucocyte elastase by lower ing 
the level o f  intact  cet-PI. A l though the phys io log ica l  
s igni f icance o f  c~l-PI inact ivat ion  by PMN leucocyte 
co l lagenase has yet to be determined,  it could  poss ib ly  
p lay an impor tant  role in the extracel lu lar  tu rnover  o f  
cel-PI,  since the enzyme is easily secreted upon  specif ic 
st imul i  [23,24] and is opt ima l ly  act ive at phys io log ic  
pH,  It has recent ly been repor ted  that  proteo lyt ica l ly  
inact ivated  cel-PI has chemotact i c  propert ies  for  
po lymorphonuc lear  leucocytes [25] and may thus 
enhance  the invas ion o f  cells. This could  lead to an ad- 
d i t iona l  release o f  PMN col lagenase and PMN elastase 
which wou ld  result in an increased turnover  o f  cel-PI 
and lung elastin. 
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